Availability and Affordability of Antidiabetic Medicines in Herat of Afghanistan in 2023 Publisher



Tajik A^{1, 2} ; Varmaghani M^{3, 4} ; Ghavami V⁵ ; Saeedi N⁶ ; Sharifi F⁷ ; Khajavi A⁸ ; Satarzadeh L⁶
Source: Journal of Diabetes and Metabolic Disorders Published:2024

Abstract

Objectives: This study aims to investigate the availability, affordability, and accessibility of antidiabetic medications in Herat, Afghanistan, in 2023. Methods: Adhering to WHO and HAI guidelines, a systematic survey approach was utilized to collect data on the pricing, availability, and affordability of commonly prescribed antidiabetic medications. Data collection spanned a month and involved four investigators using a standardized template. Data on the most-sold generic (MSG) and least expensive generic (LPG) options were compiled from pharmacies, and descriptive statistics were employed. Results: The study reveals a heavy reliance on imported medications, mainly from Pakistan, with limited local production. Availability in pharmacies exhibited notable disparities, with essential medications sometimes lacking consistency. The financial analysis identified affordability challenges, particularly for certain Iranian and Pakistani brands. Notably, Metformin 500 mg emerged as the most consumed medication. Sitagliptin 50 mg had the highest average consumption when considering Pakistani brands, whereas Insulin Regular topped the list for Iranian brands. Conclusions: The findings emphasize the need for comprehensive strategies to address diabetic patients’ challenges in Herat, Afghanistan. Strengthening the pharmaceutical supply chain, bolstering local production, and implementing measures to enhance medication affordability are crucial for improving diabetic care and advancing public health in the region. © The Author(s), under exclusive licence to Tehran University of Medical Sciences 2024.